Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2007-10-30
2007-10-30
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S145100, C435S810000, C435S335000, C435S355000, C530S387300, C530S388100, C530S388230
Reexamination Certificate
active
10938992
ABSTRACT:
In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting and/or identifying an agent that binds to an HMGB polypeptide, methods of treating a condition in a subject characterized by activation of an inflammatory cytokine cascade and methods of detecting an HMGB polypeptide in a sample.
REFERENCES:
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5545807 (1996-08-01), Surani et al.
patent: 5594114 (1997-01-01), Goodearl et al.
patent: 5605690 (1997-02-01), Jacobs et al.
patent: 5656272 (1997-08-01), Le et al.
patent: 6177077 (2001-01-01), Tobinick
patent: 6303321 (2001-10-01), Tracey et al.
patent: 6323329 (2001-11-01), Bullerdiek
patent: 6448223 (2002-09-01), Tracey et al.
patent: 6468533 (2002-10-01), Tracey et al.
patent: 2002/0009749 (2002-01-01), Ozaki et al.
patent: 2003/0017155 (2003-01-01), Tracey et al.
patent: 2003/0113323 (2003-06-01), Tracey et al.
patent: 2003/0143194 (2003-07-01), Tracey et al.
patent: 2004/0120953 (2004-06-01), Tracey et al.
patent: 2004/0141948 (2004-07-01), O'Keefe
patent: 1 079 849 (2002-01-01), None
patent: 62-166897 (1987-07-01), None
patent: 2003-096099 (2003-04-01), None
patent: WO 96/25493 (1996-08-01), None
patent: WO 97/23611 (1997-07-01), None
patent: WO 99/59609 (1999-11-01), None
patent: WO 00/47104 (2000-08-01), None
patent: WO 02/074337 (2002-09-01), None
patent: WO 02/092004 (2002-11-01), None
patent: WO 02/092004 (2002-11-01), None
patent: WO 2004/004763 (2004-01-01), None
Lederman et al., Molecular Immunology 28: 1171-1181, 1991.
Li et al., PNAS 77: 3211-3214, 1980.
Huttunen et al., Cancer Res. Aug. 15, 2002;62(16):4805-11.
Yamada, S., et al., “High Mobility Group Protein 1 (HMGB1) Quantified by ELISA With a Monoclonal Antibody That Does Not Cross-React With HMGB2,”Clin. Chem., 49(9):1535-1537 (2003).
Bustin, M., et al., “Antigenic Determinants of High Mobility Group Chromosomal Proteins 1 and 2,”Biochem., 21:6773-6777 (1982).
Reeves, R., “Molecular Biology of HMGA Proteins: Hubs of Nuclear Function,”GENE: An International Journal on Genes and Genomes, 277(1-2):63-81 (2001).
Czura, C., et al., “High Mobility Group Box-1 as a Therapeutic Target Downstream of Tumor Necrosis Factor,”J. Infect. Dis., 187 (Supp. 2):S391-S396 (2003).
Ozaki, S., et al., “Epitope Mapping of Autoantibodies to High Mobility Group (HMG) Proteins HMG1 and HMG2,”Clin. Exp. Immunol., 120 (Supp. 1):53 (2000).
Abaza, M.-S. I. and Atassi, M. Z., “Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization: Demonstration with Region 94-100 (Antigenic Site 3) of Myoglobin,”J. Protein Chem.11(5):433-444 (1992).
Abraham, E., et al., “Cutting Edge: HMG-1 as a Mediator of Acute Lung Inflammation,”J. Immunol., 165:2950-2954 (2000).
Andersson, U. et al., “High Mobility Group 1 Protein (HMG-1) Stimulates Proinflammatory Cytokine Synthesis in Human Monocytes,”J. Exp. Med., 192:565-570 (2000).
Ayer, L. M., et al., “Antibodies to HMG Proteins in Patients With Drug-Induced Autoimmunity,”Arthritis Rheum., 37(1):98-103 (1994).
Banks, G. C., et al., “The HMG-I(Y) A T-hook Peptide Motif Confers DNA-binding Specificity to a Structured Chimeric Protein,”J. Biol. Chem., 274(23):16536-16544 (1999).
Baxevanis, A.D., et al., “The HMG-1 Box Protein Family: Classification and Functional Relationships”,Nucleic Acids Res., 23(9):1604-1613 (1995).
Benjamini, E., “Antigenicity” inImmunology, A Short Course, (NY:Wiley-Liss), p. 40 (1991).
Bianchi, M. E., et al., “ Specific Recognition of Cruciform DNA by Nuclear Protein HMG1,”Science, 243:1056-1059 (1989).
Bianchi, M.E., et al., “The DNA Binding Site of HMG1 Protein is Composed of Two Similar Segments (HMG Boxes), Both of Which Have Counterparts in Other Eukaryotic Regulatory Proteins,”EMBO J.11(3):1055-1063 (1992).
Bustin, M., et al., “Immunological Relatedness of High Mobility Group Chromosomal Proteins from Calf Thymus,”J. Biol. Chem., 253(5):1694-1699 (1978).
Bustin, M. “Revised Nomenclature for High Mobility Group (HMG) Chromosomal Proteins,”Trends Biochem. Sci., 26:152-153 (2001).
Chou, D. K. H., et al., “Identity of Nuclear High-Mobility-Group Protein, HMG-1, and Sulfoglucuronyl Carbohydrate-Binding Protein, SBP-1, in Brain,”J. Neurochem., 77:120-131 (2001).
Clackson, T., et al., “Making Antibody Fragments Using Phage Displays Libraries,”Nature, 352:624-628 (1991).
Colman, P. M., “Effects of Amino Acid Sequence Changes on Antibody-Antigen Interactions,”Res. Immunol., 145(1):33-36 (1994).
Czura, C., et al., “Dual Roles for HMGB1:DNA Binding and Cytokine,”J. Endotoxin Res.,7(4):315-321 (2001).
Daston, M. and Ratner, N., “Expression of P30, a Protein with Adhesive Properties, in Schwann Cells and Neurons of the Developing and Regenerating Peripheral Nerve,”J. Cell Biol., 112(6):1229-1239 (1991).
Degryse, B., et al., “The High Mobility Group (HMG) Boxes of the Nuclear Protein HMG1 Induce Chemotaxis and Cytoskeleton Reorganization in Rat Smooth Muscle Cells,”J. Cell Biol., 152:1197-1206 (2001).
Falciola, L., et al., “High Mobility Group 1 Protein is Not Stably Associated with the Chromosomes of Somatic Cells,”J. Cell Biol., 137 (1):19-26 (1997).
Freeman, B. D., et al., “The Role of Inflammation in Sepsis and Septic Shock: A Meta-Analysis of Both Clinical and Preclinical Trials of Anti-Inflammatory Therapies,” inInflammation: Basic Principals and Clinical Correlates(John I. Gallin and Ralph Snyderman eds., Lippincott, Williams & Wilkins, Philadelphia, 3rded. 1999), pp. 965-975.
Imamura, T., et al., “Interaction with p53 Enhances Binding of Cisplatin-Modified DNA by High Mobility Group 1 Protein,”J. Biol. Chem., 276(10):7534-7540 (2001).
Ise, T., et al., “Transcription Factor Y-Box Binding Protein 1 Binds Preferentially to Cisplatin-Modified DNA and Interacts With Proliferating Cell Nuclear Antigen,”Cancer Res., 59:342-346 (1999).
Jakobovits, A., et al., “Germ-Line Transmission and Expression of a Human-Derived Yeast Artificial Chromosome,”Nature, 362:255-258 (1993).
Jakobovits, A., et al., “Analysis of Homozygous Mutant Chimeric Mice: Deletion of the Immunoglobulin Heavy-Chain Joining Region Blocks B-Cell Development and Antibody Production,”Proc. Natl. Acad. Sci. USA, 90:2551-2555 (1993).
Kuby, J.,Immunology, (New York, W.H. Freeman and Company) p. 1 (1992).
Johns, E.W., et al., “History, Definitions and Problems”, inThe HMG Chromsomal Problems, (Academic Press), London: Chapter 1, pp. 1-7 (1982).
Jung, F., et al., “Antibodies Against a Peptide Sequence Located in the Linker Region of the HMG-1/2 Box Domains in Sera From Patients With Juvenile Rheumatoid Arthritis,”Arthritis Rheum., 40(10):1803-1809 (1997).
Landsman, D., et al., “A Signature for the HMG-1 Box DNA-Binding Proteins”,BioEssays, 15(8):539-546 (1993).
Lederman, S., et al., “A Single Amino Acid Substitution in a Common African Allele of the CD4 Molecule Ablates Binding of the Monoclonal Antibody OKT,”Mol. Immunol., 28(11):1171-1181 (1991).
Lotze, M.T., and K. J. Tracey, “High-Mobility Group Box 1 Protein (HMGB1): Nuclear Weapon in the Immune Arsenal”,Nature Rev. Immunol.5:331-342 (2005).
Ma, W., et al. “Detection of Anti-Neutrophil Cytoplasmic Antibodies in MRL/Mp-lpr/lprMice and Analysis of Their Target Antigens,”Autoimmunity, 32(4):281-291 (2000).
Marks, J. D., et al., “By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling,”Bio/Technology, 10:779-783 (1992).
Melloni, E., et al., “Extracellular Release of th
Newman Walter
O'Keefe Theresa L.
Obar Robert A.
Qin Shixin
Critical Therapeutics, Inc.
Gambel Phillip
Hamilton Brook Smith & Reynolds P.C.
Skelding Zachary
LandOfFree
Monoclonal antibodies against HMGB1 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibodies against HMGB1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibodies against HMGB1 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3833567